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Abstract
Objective:  To  describe  the  efﬁcacy  and  safety  of  chloral  hydrate  sedation  in  infants  for  pul-
monary function  tests.
Methods:  All  sedation  attempts  for  pulmonary  function  tests  in  infants  carried  out  between
June 2007  and  August  2014  were  evaluated.  Obstructive  sleep  apnea  and  heart  disease  were
contraindications  to  the  exams.  Anthropometric  data,  exam  indication,  used  dose,  outcomes
of sedation  and  clinical  events  were  recorded  and  described.
Results:  The  sedation  attempts  in  277  infants  (165  boys)  with  a  median  age  of  51.5  weeks  of  life
(14--182 weeks)  were  evaluated.  The  main  indication  for  the  tests  was  recurrent  wheezing  (56%)
and the  chloral  hydrate  dose  ranged  from  50  to  80mg/kg  (orally).  Eighteen  (6.5%)  infants  had
some type  of  clinical  complication,  with  the  most  frequent  being  cough  and/or  airway  secretion
(1.8%); respiratory  distress  (1.4%)  and  vomiting  (1.1%).  A  preterm  infant  had  bradycardia  for
approximately  15  minutes,  which  was  responsive  to  tactile  stimulation.  All  observed  adverse
effects were  transient  and  there  was  no  need  for  resuscitation  or  use  of  injectable  medications.
Conclusions:  The  data  demonstrated  that  chloral  hydrate  at  the  employed  doses  is  a  safe  and
effective medicament  for  sedation  during  short  procedures  in  infants,  such  as  pulmonary  func-
tion tests.  Because  of  the  possibility  of  severe  adverse  events,  recommendations  on  doses  and
contraindications  should  be  strictly  followed  and  infants  should  be  monitored  by  trained  staff.
© 2016  Sociedade  de  Pediatria  de  Sa˜o  Paulo.  Published  by  Elsevier  Editora  Ltda.  This  is  an  open
access article  under  the  CC  BY  license  (http://creativecommons.org/licenses/by/4.0/).
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Eﬁcácia  e  seguranc¸a  do  hidrato  de  cloral  na  sedac¸ão de  lactentes  para  testes
de  func¸ão  pulmonar
Resumo
Objetivo:  Descrever  a  eﬁcácia  e  a  seguranc¸a do  hidrato  de  cloral  na  sedac¸ão  de  lactentes  para
testes de  func¸ão  pulmonar.
Métodos:  Foram  avaliadas  retrospectivamente  todas  as  tentativas  de  sedac¸ão  para  exames  de
func¸ão pulmonar  em  lactentes  feitas  entre  junho  2007  e  agosto  2014.  Apneia  obstrutiva  do
sono e  cardiopatia  foram  contraindicac¸ões  para  os  exames.  Dados  antropométricos,  indicac¸ão
do exame,  dose  empregada,  desfechos  da  sedac¸ão  e  intercorrências  clínicas  foram  registrados
e descritos.
Resultados:  Avaliaram-se  as  tentativas  de  sedac¸ão  de  277  lactentes  (165  meninos)  com  mediana
de 51,5  semanas  de  vida  (14-182).  A  principal  indicac¸ão  para  os  testes  foi  sibilância  recorrente
(56%) e  a  dose  de  hidrato  de  cloral  usada  variou  entre  50-80mg/kg  (via  oral).  Dezoito  (6,5%)
lactentes apresentaram  algum  tipo  de  intercorrência  clínica  e  foram  as  mais  frequentes:  tosse
e/ou secrec¸ão  na  via  aérea  (1,8%);  desconforto  respiratório  alto  (1,4%)  e  vômitos  (1,1%).  Um
lactente prematuro  apresentou  bradicardia  por  cerca  de  15  minutos,  responsiva  a  estimulac¸ão
tátil. Todos  os  efeitos  adversos  observados  foram  transitórios  e  não  houve  necessidade  de
manobras  de  reanimac¸ão  e  uso  de  medicac¸ões  injetáveis.
Conclusões:  Os  dados  demonstraram  que  o  hidrato  de  cloral,  nas  doses  empregadas,  é  um
medicamento  seguro  e  eﬁcaz  para  a  sedac¸ão  de  lactentes  em  procedimentos  de  curta  durac¸ão,
como os  testes  de  func¸ão  pulmonar.  Devido  à  possibilidade  de  eventos  adversos  graves,  as
recomendac¸ões referentes  à  dosagem  e  contraindicac¸ões  devem  ser  seguidas  de  forma  rígida  e
os lactentes  devem  ser  monitorados  por  equipe  treinada.
© 2016  Sociedade  de  Pediatria  de  Sa˜o  Paulo.  Publicado  por  Elsevier  Editora  Ltda.  Este e´  um
artigo Open  Access  sob  uma  licenc¸a  CC  BY  (http://creativecommons.org/licenses/by/4.0/).
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iIntroduction
Chloral  hydrate  (CH)  is  a  hypnotic  sedative  drug  widely  used
in  recent  decades  to  sedate  children.  Although  its  exact
mechanism  of  action  remains  uncertain,  the  CH  is  metabo-
lized  to  trichloroethanol,  the  active  metabolite  responsible
for  the  hypnotic  effects.  The  half-life  of  this  metabolite  is
8--12h  in  preschoolers,  but  can  be  up  to  four  times  longer  in
newborns  and  preterm  infants.1,2
CH  is  the  sedative  of  choice  for  pulmonary  function
tests  in  infants  and  has  been  used  in  several  laboratories
for  more  than  25  years.1,3 It  is  the  drug  of  choice  due  to
several  factors.  It  is  administered  orally,  does  not  require
venipuncture  and  induces  adequate  sedation  degree  and
duration  for  pulmonary  function  assessment  procedures  to
be  carried  out.1 Additionally,  the  available  reference  equa-
tions  for  pulmonary  function  parameters  were  obtained
after  sedation  with  CH  and  use  of  other  sedatives  could
hinder  comparisons  and  induce  biases.3 In  a  recent  sur-
vey  carried  out  at  148  pulmonary  function  laboratories  in
infants  worldwide,  79%  of  them  used  CH  as  a  sedative  for
exams.4
The  use  of  CH  for  sedation  in  young  children,  however,
is  not  a  consensus  and  severe  adverse  events,  including
deaths,  have  been  reported.2,5 Recently,  the  Brazilian
National  Health  Surveillance  Agency  (ANVISA)  has  banned
the  sale  of  CH  in  the  country  for  lack  of  evidence  of  its
efﬁcacy  and  safety.  The  aim  of  this  article  is  to  describe  the
experience  of  the  pulmonary  function  laboratory  in  infants
treated  at  the  Discipline  of  Allergy,  Clinical  Immunology  and
Rheumatology  of  the  Department  of  Pediatrics  of  Escola
t
v
s
caulista  de  Medicina  (Unifesp)  regarding  the  use  of  CH  in
ecessary  sedation  for  pulmonary  function  tests.
ethod
his  is  a  retrospective  case  series,  which  evaluated  all
edation  attempts  for  pulmonary  function  tests  in  infants
etween  June  2007  and  August  2014.  The  pulmonary  func-
ion  tests  were  carried  out  in  infants  weighing  ≥4kg  and  no
istory  of  respiratory  infection  in  the  previous  two  weeks.
n  the  day  of  the  pulmonary  function  test,  the  infants  that
ame  to  the  service  had  fasted  for  at  least  3h  and  received
n  oral  dose  of  chloral  hydrate  after  clinical  evaluation.  All
ests  were  performed  with  the  infant  in  the  supine  position
ith  slight  neck  extension  and  tests  were  carried  out  with
ontinuous  heart  rate  and  oxygen  saturation  monitoring.  A
hysician  and  a  physical  therapist  trained  in  emergency  care
ere  present  in  all  examinations  and  resuscitation  equip-
ent  was  available  during  all  tests.
Lung  volumes  and  forced  expiratory  ﬂow  were  measured
sing  speciﬁc  equipment  (Infant  Pulmonary  Lab,  Collins-
Spire,  USA),  according  to  existing  recommendations.6,7
n  brief,  lung  volume  was  measured  during  the  infants’
pontaneous  breathing  movements;  then,  the  airway  was
ccluded  for  a  few  seconds,  at  some  moments  during  breath-
ng.  Forced  expiratory  ﬂows  were  obtained  using  the  rapid
horacoabdominal  compression  technique  with  high  lung
olumes.  Flow-volume  curves  were  obtained  by  compres-
ion  of  an  inﬂatable  jacket  placed  around  the  infant’s
hest  and  abdomen  after  inspiration  with  positive  pressure
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30cm/H2O).  Chest  and  abdomen  compression  was  main-
ained  until  the  end  of  expiration  was  visually  identiﬁed
r  for  a  maximum  period  of  four  seconds.  Several  curves
ere  obtained  with  increasing  thoracoabdominal  compres-
ion  pressure,  until  there  was  no  increase  in  forced  ﬂow  and
olume  values.
To evaluate  the  safety  and  efﬁcacy  of  CH  in  this
tudy,  anthropometric  data,  test  indication,  CH  dose
mployed  (per  kg  of  bodyweight)  and  sedation  outcome
ere  recorded,  as  well  as  successful  sedation  and  pulmonary
unction  assessment.  In  cases  of  clinical  complications,  the
ature  of  these  complications  and  required  procedures  were
ecorded.
All  tests  were  performed  after  obtaining  written  consent
rom  parents  and/or  guardians  and  after  approval  of  the
nstitutional  Review  Board  of  Universidade  Federal  de  São
aulo  (Unifesp).
esults
 total  of  277  infants  were  assessed  (165  males),  with  a
edian  age  of  51.5  weeks  (range  14--182).  The  indications
or  the  tests  were:  prematurity  and/or  low  birth  weight  in  74
27%),  recurrent  wheezing  and/or  lung  disease  in  156  (56%),
ickle-cell  anemia  in  13  (5%)  and  others  in  34  (12%)  infants.
CH  dose  ranged  from  50  to  80mg/kg  (orally),  with  a
edian  of  70mg/kg.  This  dose  usually  induces  sleep  quickly
in  approximately  20min)  and  maintains  it  for  approximately
0min.  Of  the  attempted  assessments,  it  was  not  possible  to
erform  the  pulmonary  function  test  in  32  (12%)  cases:  18
6.5%)  due  to  problems  in  sedation  (9  infants  did  not  sleep
nd  9  awakened  too  soon),  10  (4%)  due  to  clinical  problems
nd  4  (1%)  due  to  technical  difﬁculties.  Clinical  problems
hat  prevented  the  assessment  from  being  performed  were
ough  (2  infants);  respiratory  distress  (1);  vomiting  (3);  pres-
nce  of  airway  secretions  (1);  decrease  in  peripheral  oxygen
aturation  (SpO2)  (1);  bradycardia  (1)  and  upper  airway
bstruction  (1).
In  the  245  pulmonary  function  tests  performed,  clini-
al  events  were  observed  during  the  examination  in  eight
nfants  (3%).  Thus,  of  the  277  sedation  attempts,  18  (6.5%)
nfants  showed  some  type  of  clinical  complication  after  CH
dministration.  The  observed  adverse  events  are  shown  in
able  1.The  actions  required  in  these  cases  were  upper  airway
spiration,  cervical  repositioning  and  oxygen  supplemen-
ation.  The  child  that  had  bradycardia  was  a  preterm
nfant,  born  at  27  weeks  of  gestation  weighing  770g,
Table  1  Adverse  events  observed  after  administration  of
chloral  hydrate  in  277  infants.
Number  Percentage
Cough  and/or  airway  secretion  5  1.8
Upper respiratory  distress  4  1.4
Vomiting  3  1.1
Decrease  in  oxygen  saturation  2  0.7
Abdominal  distension  2  0.7
Prolonged  hiccups  1  0.4
Bradycardia  1  0.4
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nd  a chronological  age  of  11  months  at  the  time  of  the
xamination.  After  sedation  with  75mg/kg  of  CH,  the  heart
ate  decreased  for  about  15min,  not  lower  than  65bpm,
eing  responsive  to  tactile  stimulation.
All  adverse  events  observed  during  the  277  sedation
ttempts  were  transient,  with  spontaneous  improvement
fter  the  end  of  CH  action.  There  were  no  cases  that
equired  ventilation  and  resuscitation  maneuvers,  use  of
njectable  medications  or  hospitalization.
iscussion
H-induced  sedation  is  considered  of  moderate  intensity
nd,  therefore,  it  is  recommended  that  it  be  performed
nder  the  supervision  of  physicians  and  health  professionals
rained  in  life  support,  with  available  resuscitation  equip-
ent  and  infant  monitoring.
It is  known  that  the  CH  can  reduce  upper  airway  mus-
le  tone  and  increase  the  chance  of  collapse  in  infants
ith  some  degree  of  upper  airway  obstruction,  such  as
hose  with  pharyngeal  and  palatine  tonsil  hypertrophy,
bstructive  sleep  apnea  and  craniofacial  abnormalities.1
or  this  reason,  such  conditions  contraindicate  pulmonary
unction  test  performance  in  our  laboratory.  Similarly,
xaminations  are  not  carried  out  in  infants  with  heart
isease  due  to  the  potential  cardiac  depression  and  induc-
ion  of  conduction  disorders  caused  by  CH,  which  causes
rrhythmias.1
Some  comments  about  our  data  are  important.  Overall,
ur  ﬁndings  reinforce  data  from  other  services  and  demon-
trate  the  safety  and  efﬁcacy  of  CH  as  a  sedative  to  be  used
or  procedures  in  infants.8--10
The  CH  dose  used  by  us  (50--80mg/kg)  was  similar  to  that
mployed  by  other  investigators4 and  sedation  failure  was
bserved  in  only  6.5%  of  the  attempts.  Higher  doses  of  the
edative  and/or  repeated  doses  could  reduce  the  number  of
ailures,  but  are  associated  with  increased  risk  of  adverse
vents.1 West  et  al.  evaluated  the  efﬁcacy  and  safety  of
H  in  infants  and  preschoolers  for  ophthalmic  procedures.9
sing  a  dose  of  80mg/kg  of  CH,  they  observed  inadequate
edation  in  7.2%  of  children.  An  additional  dose  of  up  to
0mg/kg  was  administered  in  cases  of  failure,  with  sedation
ailure  being  reduced  to  3.3%.9
In  our  service,  we  observed  an  incidence  of  6.5%  of
dverse  events.  The  observed  adverse  events  and  their  fre-
uency  were  similar  to  those  described  by  other  authors,
hat  is:  paradoxical  reactions  (1.3%);  decrease  in  SpO2
1%);  vomiting  (0.5%)  and  bradycardia  (0.1%).9 The  report
f  another  large  case  series,  by  Avlonitou  et  al.  compiled
dverse  events  after  sedation  with  CH  for  hearing  tests  in
903  children  up  to  14  years  of  age  (568  children  under  six
onths  of  age).8 In  this  study,  they  observed  hyperactivity
n  8%  of  cases,  vomiting  in  11%,  mild  respiratory  discomfort
.5%  and  apnea  in  0.2%  of  the  cases.8
Prematurity  and  younger  age  are  factors  known  to  be
ssociated  with  increased  risk  of  adverse  events  after  seda-
ion  with  CH.10 These  two  factors  were  present  in  the  case
f  the  infant  who  had  bradycardia  in  our  laboratory.  As
bserved  by  us,  other  authors  have  reported  that  cases  of
radycardia  induced  by  CH  tend  to  be  responsive  to  physical
timuli,  with  good  evolution.9,10
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The  safety  of  CH  (80mg/kg)  has  also  been  studied  in  a
group  of  1095  children  (aged  between  one  month  and  three
years)  sedated  for  echocardiograms.11 In  this  risk  group,  con-
sisting  mostly  of  patients  with  heart  disease,  10.8%  had  some
adverse  event,  such  as  decrease  in  SpO2 (5.9%),  hypercapnia
(6.6%),  airway  obstruction  (1.4%),  apnea  (0.3%),  hypoten-
sion  (0.4%)  and  vomiting  (0.4%).  Of  the  assessed  children,
24%  showed  a  decrease  in  heart  rate  ≥20%,  but  only  1.4%
decreased  heart  rate  below  the  normal  range  for  age.11
Major  interventions  such  as  face-mask  ventilation  and  vol-
ume  expansion  were  necessary  in  ﬁve  cases  (<0.5%),  with
tracheal  intubation  in  one  of  them.11
A  review  of  adverse  event  reports  associated  with  seda-
tion  in  North-American  children  identiﬁed  95  severe  cases
reported  by  the  end  of  the  1990s.5 Of  these,  20  were  related
to  the  use  of  CH,  with  13  cases  leading  to  death  or  perma-
nent  neurological  damage.  Among  these  more  severe  cases,
CH  was  administered  alone  in  seven  patients  and  in  combi-
nation  with  other  drugs  in  six.5 CH  overdose  was  identiﬁed
in  four  cases  and  nine  had  pre-existing  clinical  problems,
such  as  tracheomalacia,  tracheostomy,  genetic  syndromes,
congenital  heart  defects  and  cerebral  palsy.5
Despite  the  existence  of  these  severe  adverse  event
reports,  CH  has  been  administered  for  pulmonary  function
tests  in  a  large  number  of  studies  involving  thousands  of
infants  with  respiratory  problems,  with  a  low  incidence
of  adverse  events  and  no  report  of  death  or  permanent
sequelae.1
Several  other  sedative  drug  options  for  infants  are  avail-
able,  each  showing  speciﬁc  advantages  and  disadvantages.
Midazolam  is  a  short-duration  benzodiazepine  that  is  widely
used  in  clinical  practice,  especially  intravenously.  In  addi-
tion  to  the  need  for  venous  access,  midazolam  can  also  cause
respiratory  depression  and  hypotension.12 The  main  advan-
tage  of  midazolam  is  the  availability  of  an  antagonist  able
to  reverse  its  effects.12 More  recently,  the  intranasal  for-
mulation  of  midazolam  has  been  developed,  which  is  more
convenient  for  outpatient  procedures,  but  with  less  seda-
tive  action.  Dexmedetomidine  is  a  selective  2-adrenergic
agonist  capable  of  inducing  sedation  and  slight  analgesia,
used  in  several  diagnostic  procedures.13 It  is  preferably
administered  intravenously,  with  a  small  failure  rate,  and
its  most  common  adverse  effects  are  bradycardia  and
blood  pressure  changes.13,14 The  effect  of  dexmedetomi-
dine  on  the  respiratory  system  is  small  and,  unlike  CH,  the
sedative  seems  to  be  safe  in  children  with  upper  airway
obstructive  disorders,  but  studies  in  young  children  are  still
limited.14
In  conclusion,  the  data  obtained  in  our  service  are  sim-
ilar  to  those  observed  by  other  authors  and  demonstrate
that  CH,  at  the  assessed  doses,  is  a  safe  and  effective
drug  for  infant  sedation  during  short  procedures,  such  as
pulmonary  function  tests.  Due  to  the  possibility  of  severe
adverse  events,  dose  recommendations  and  contraindica-
tions  to  the  use  of  CH  should  be  strictly  followed.  Sedation
with  CH  should  always  be  carried  out  by  trained  staff,  under
medical  supervision  and  continuous  monitoring  of  infants.
1411
pecial  attention  should  be  given  to  infants  belonging  to  risk
roups,  such  as  preterm  infants.
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